Sunitinib in Pancreatic Neuroendocrine Tumors. Clinical Case

Medical Council
doi 10.21518/2079-701x-2019-19-114-118
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Remedium, Ltd.

Related search

Sunitinib in Advanced Pancreatic Neuroendocrine Tumors: Latest Evidence and Clinical Potential

Therapeutic Advances in Medical Oncology
Oncology
2011English

PCN16 Clinical Effectiveness Analysis of Sunitinib for the Treatment of Pancreatic Neuroendocrine Tumors

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Role of Sunitinib for the Management of Pancreatic Neuroendocrine Tumors

Gastrointestinal Cancer: Targets and Therapy
2011English

Pancreatic Neuroendocrine Tumors

Revista Espanola de Enfermedades Digestivas
MedicineGastroenterology
2017English

PCN63 Cost-Effectiveness of Sunitinib in Patients With Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Promising Developments for Pancreatic Neuroendocrine Tumors

Cancer Discovery
Oncology
2011English

Risk Factors for Pancreatic Neuroendocrine Tumors

Pancreas
Internal MedicineEndocrinologyHepatologyMetabolismDiabetes
2014English

Molecular Pathogenesis of Pancreatic Neuroendocrine Tumors

Cancers
Cancer ResearchOncology
2010English

Small Pancreatic Neuroendocrine Tumors: Resect or Enucleate?

HPB
HepatologyGastroenterology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy